ArticleJournal of clinical medicine2021

Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib.

Damian Mikulski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.